Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cutting a wider margin around brain tumors extend survival?

NCT ID NCT04737577

Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This pilot trial asks whether removing a wider margin of brain tissue around a high-grade glioma—beyond the standard visible tumor boundary—can improve survival without causing more neurological harm. It enrolls adults with a first-time diagnosis of high-grade glioma in a surgically safe location. Participants are randomly assigned to either standard removal of the enhancing tumor or a supra-marginal resection that extends at least 1 cm into surrounding tissue. The study primarily tests whether a larger trial is feasible, while also tracking survival, neurological function, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Supra-marginal surgical resection (removing a wider margin of brain tissue around the tumor)
What this could lead to
If successful, this could show that a wider surgical margin improves survival for people with high-grade glioma, potentially changing standard surgical practice.
What could go wrong
This is a small pilot study focused on feasibility, not a definitive test of survival benefit. Removing more brain tissue may increase the risk of neurological problems, and results may not apply to all glioma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Feb 2021

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Radiographic evidence of a GAD-enhancing intra-axial tumor consistent with HGG; 2. Age ≥18 ≤ 85 years; 3. Karnofsky Performance Score ≥ 60; 4. Location of tumor in a safe anatomical location and 5. Patient or substitute decision maker (SDM) able to understand and consent to study participation. Exclusion Criteria: 1. Multi-focal tumor, gliomatosis cerebri (≥3 lobes of the brain affected), tumors crossing the midline, or leptomeningeal enhancement; 2. Previous craniotomy for tumor excision (stereotactic biopsy is permitted); 3. Known metastatic cancer; 4. Uncorrectable coagulopathy; 5. Unable to obtain GAD-enhanced brain MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High grade glioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

High grade glioma

Contacts and locations

Locations

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

  • Mackenzie Health Sciences Center

    Edmonton, Alberta, T6G 2B7, Canada

  • St Michael's Hospital

    Toronto, Ontario, M5B 1W8, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • The Pennsylvania State University

    University Park, Pennsylvania, 16802, United States

  • University of Saskatchewan

    Saskatoon, Saskatchewan, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.